624 Shares in Stryker Co. (NYSE:SYK) Acquired by M. Kraus & Co

M. Kraus & Co purchased a new position in Stryker Co. (NYSE:SYKFree Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 624 shares of the medical technology company’s stock, valued at approximately $223,000.

Other institutional investors also recently added to or reduced their stakes in the company. Burkett Financial Services LLC acquired a new stake in Stryker during the fourth quarter worth approximately $25,000. Farmers & Merchants Trust Co of Chambersburg PA raised its holdings in Stryker by 203.3% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Rogco LP acquired a new stake in Stryker during the fourth quarter worth approximately $30,000. DSM Capital Partners LLC acquired a new stake in Stryker during the fourth quarter worth approximately $34,000. Finally, HBC Financial Services PLLC acquired a new stake in Stryker during the fourth quarter worth approximately $37,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK traded up $1.29 during trading on Friday, hitting $342.64. 1,811,620 shares of the company were exchanged, compared to its average volume of 1,323,144. The company has a market cap of $130.53 billion, a price-to-earnings ratio of 39.11, a PEG ratio of 2.75 and a beta of 0.92. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The firm’s fifty day moving average price is $336.68 and its 200 day moving average price is $331.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.71 and a quick ratio of 0.99.

Stryker (NYSE:SYKGet Free Report) last issued its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.36 by $0.14. The company had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.14 EPS. On average, sell-side analysts expect that Stryker Co. will post 11.95 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be given a $0.80 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 0.93%. Stryker’s dividend payout ratio is presently 36.53%.

Analysts Set New Price Targets

A number of brokerages have recently commented on SYK. Royal Bank of Canada lifted their target price on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. The Goldman Sachs Group began coverage on shares of Stryker in a report on Thursday, May 30th. They issued a “neutral” rating and a $372.00 target price on the stock. Roth Mkm lifted their target price on shares of Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. TD Cowen lifted their target price on shares of Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Finally, UBS Group lifted their target price on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $370.58.

View Our Latest Stock Report on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.